|Bid||0.7275 x 2900|
|Ask||0.7300 x 1300|
|Day's Range||0.7250 - 0.7643|
|52 Week Range||0.7250 - 3.0500|
|Beta (5Y Monthly)||1.02|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 23, 2022 - Feb 28, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.00|
BASKING RIDGE, N.J., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, today announced its participation in several industry and investor events. All presentations are pre-recorded and available on-demand through the online conference platforms. Biotech Showcase (January 10–12, 2022 and January 17–19, 2022
Investors need to pay close attention to Caladrius (CLBS) stock based on the movements in the options market lately.
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...